Japan · Delayed Price · Currency is JPY Astellas Pharma Earnings Call Transcripts
Fiscal Year 2026
-
A new five-year plan targets sustainable, pipeline-led growth, doubling strategic brand sales, and record revenues by the mid-2030s. Major R&D investments focus on oncology, including KRAS and Claudin 18.2 programs, with disciplined cash allocation and cost optimization supporting profitability.
-
Record-high revenue and profit were achieved, driven by strong growth in strategic brands and effective cost optimization. FY 2026 guidance projects continued double-digit profit growth, increased R&D investment, and a stable dividend policy, while monitoring risks from U.S. pricing and patent expirations.
-
Multiple flagship assets achieved proof of concept, with phase III trials underway in key indications. Strategic focus, disciplined portfolio management, and digital transformation are driving pipeline progress and operational efficiency, supporting long-term growth and financial targets.
-
Q3 FY2025 saw double-digit revenue and profit growth, driven by strategic brands and cost optimization. Full-year forecasts were revised upward, with strong sales from PADCEV, IZERVAY, VYLOY, VEOZAH, and XTANDI, and significant pipeline progress supporting future growth.
-
A diversified portfolio of five strategic brands is set to drive growth and profitability after XTANDI's loss of exclusivity, with a focus on R&D innovation and financial discipline. The company targets a 30% operating profit margin by FY 2027, supported by cost optimization and a robust pipeline.
-
Revenue and profits grew sharply year-on-year, driven by strategic brands and cost optimization. Full-year forecasts were revised upward, with strong pipeline progress and stable dividend policy maintained.
-
Q1 FY2025 saw strong revenue and profit growth, led by strategic brands and cost optimization. Pipeline progress and new licensing agreements support future growth, while cost savings are being reinvested. Full-year guidance will be reviewed after Q2.
Fiscal Year 2025
-
Record FY 2024 results were driven by strong growth in strategic brands and cost optimization, with revenue up 19% and core operating profit up 42% year-over-year. FY 2025 guidance anticipates continued double-digit profit growth, robust expansion of key brands, and ongoing cost discipline.
-
ASP3082, a first-in-class TPD targeting KRAS G12D, shows promising safety and antitumor activity in early-phase trials for PDAC and NSCLC, with ongoing dose escalation and combination studies. Strategic investments and pipeline expansion continue, with proof of concept expected by mid-2025.
-
Revenue and profit surged year-over-year, driven by strong growth in strategic brands and Xtandi, prompting an upward revision of full-year forecasts. Strategic brands like PADCEV and IZERVAY saw rapid expansion, while cost optimization and R&D investments support future growth.
-
Q1 FY2024 saw revenue rise 26% year-on-year, led by XTANDI and strategic brands, with strong U.S. performance and robust growth in Padcev and Izervay. Strategic brands sales tripled, and profit metrics improved, while cost management and ROI-focused investments supported growth.
Fiscal Year 2024
-
ASP3082, a first-in-class TPD targeting KRAS G12D, shows promising safety and antitumor activity in early trials for solid tumors, with dose escalation ongoing and proof of concept expected by H1 2025. The pipeline is expanding with advanced technology and combination regimens already in progress.